Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
162actual
Sites
53
Countries
Australia, Belgium, Canada +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2010-02-04 | actual | When the study began enrolling |
| Primary completion | 2011-10-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2010-03-05 | estimated | When this record first appeared on the registry |
| Results posted | 2012-12-10 | estimated | When the sponsor posted results to the registry |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ovarian Cancer
Interventions
- Drug: olaparib — also filed as Lynparza
- Drug: paclitaxel — also filed as Taxol
- Drug: carboplatin
- Drug: paclitaxel
- Drug: Drug: carboplatin
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival (PFS)
measured Radiologic scans performed at weeks 9 and 18 (+/-1 week) and every 12 weeks thereafter relative to the date of randomisation until the primary analysis (approximately 20 months)
Publications
- PMID 35170751 — linked by the registry
- PMID 25554012 — linked by the registry
- PMID 25481791 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed